### Sunday, March 7, 2010

# 12:00 p.m.-2:00 p.m. Concurrent Educational Workshops 1

### Session 1A: Grant Writing and International Funding Sources

Dead Sea 1 & 2

Chairperson: Geoffrey M. Wahl, Salk Institute Cancer Center, La Jolla, CA, USA

### Do's and don'ts of grant writing

Geoffrey M. Wahl

### The craft of grantsmanship: "Writing stories that sell the science"

Carol Winkelman, Science Writer, Chapel Hill, NC, USA

Additional Speaker to be announced

### Session 1B: Comprehensive Cancer Centers: Importance, Impact, and Implementation

Mount Nebo 1 & 2

**Chairperson: Jean-Pierre Armand,** Institut Claudius Regaud, Toulouse, France

### Searching for new drugs: The foxes and the mammoths

Jean-Pierre Armand

# Translational research: A critical mission of a comprehensive cancer center - the example of vitamin D

Donald L. Trump, Roswell Park Cancer Institute, Buffalo, NY

# Comprehensive cancer centers and their role in the development of personalized medicine

William S. Dalton, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

# 2:15 p.m.-4:15 p.m. Concurrent Educational Workshops 2

# Session 2A: Clinical Research and Clinical Trial Design

Mount Nebo 1 & 2

**Chairperson: Martine J. Piccart-Gebhart,** Institut Jules Bordet, Brussels, Belgium

# Incorporation of translational science into clinical trials: The NEO-BIG initiative

Martine J. Piccart-Gebhart

### Integrating biomarkers in clinical research: Statistical considerations

Marc E. Buyse, International Drug Development Institute, Ottignies, Belgium

### Biomarker-driven drug development: From dream to reality

Mace L. Rothenberg, Pfizer, Inc., San Diego, CA, USA

Finding the positive in triple negative breast cancer Lisa A. Carey, University of North Carolina, Chapel Hill, NC, USA

# Session 2B: Scientific Writing and the Publication Process

Dead Sea 1 & 2

**Chairperson: Tom Curran,** Children's Hospital of Philadelphia, Philadelphia, PA, USA

# Research grant writing: Process, ethics, and confidentiality

Youcef M. Rustum, Roswell Park Cancer Institute, Buffalo, NY, USA

### Dealing with the necessary evils: Editors and reviewers

Tom Curran

### Increasing your chances for publication in top journals Margaret Foti, American Association for Cancer Research, Philadelphia, PA

#### **Publishing: The key to immortality**

Joe B. Harford, National Cancer Institute, Bethesda, MD, USA

# 4:30 p.m.-6:30 p.m. Concurrent Educational Workshops 3

#### **Session 3A: Politics and Ethics of Cancer Research**

Mount Nebo 1 & 2

**Chairperson: William S. Dalton,** H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Are there universal elements in navigating the political environment to improve the climate for cancer research?

William S. Dalton

#### Title to be announced

Deborah Schrag, Dana-Farber Cancer Institute, Boston, MA, USA

Additional Speakers to be announced

#### **Session 3B: New Technologies**

Dead Sea 1 & 2

**Chairperson: Joe W. Gray,** Lawrence Berkeley National Laboratory, Berkeley, CA, USA

#### Title to be announced

Jan T. Liphardt, University of California - Berkeley, Berkeley, CA, USA

**New technologies for early cancer detection** Joe W. Gray

Methylome analysis of breast cancer progression Saraswati Sukumar, Johns Hopkins University School of Medicine, Baltimore, MD, USA

#### 7:00 p.m.-8:30 p.m. Opening Session

Dead Sea 1 & 2

**Chairperson: Samir N. Khleif,** National Cancer Institute, Bethesda, MD, USA

Speakers to be announced

#### 8:30 p.m.-10:00 p.m. Opening Reception

Terrace

### Monday, March 8, 2010

### 9:00 a.m.-11:00 a.m. Scientific Workshop 1: Signal Transduction Pathways

Dead Sea 1 & 2

**Chairperson: Pier Paolo Pandolfi,** Beth Israel Deaconess Medical Center, Boston, MA, USA

#### Title to be announced

Pier Paolo Pandolfi

### The role of PI3K pathway in the regulation of the immune system

Samir N. Khleif, National Cancer Institute, Bethesda, MD, USA

### Multiple approaches to targeting the PI3K pathway in cancer

Lori S. Friedman, Genentech, Inc., South San Francisco, CA, USA

### Role of ERBB3/PI3K in mammary oncogenesis and resistance to targeted therapies

Carlos Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

11:30 a.m.-1:30 p.m. Scientific Symposium 1: Tumor Microenvironment and Genomics

Dead Sea 1 & 2

**Chairperson: Thea D. Tlsty,** University of California School of Medicine, San Francisco, CA, USA

3-D spheroid cultures as model systems for novel anticancer drug discovery

Kristiina Vuori, Burnham Institute for Medical Research, La Jolla, CA, USA

The tumor microenvironment as target for cancer therapy and prevention: A role for anti-inflammatory antiangiogenic molecules

Adriana Albini, Polo Scientifico e Tecnologico, IRCCS Multimedica, Milan, Italy

TGF $\beta$ -1-mediated modulation of the DNA damage response in human mammary cells

Beverly M. Emerson, Salk Institute for Biological Studies, La Jolla, CA, USA

**Molecular alterations that predict malignancy** Thea D. Tlsty

1:30 p.m.-3:30 p.m. Poster Session A and Lunch

Wadi Rum 1 & 2

3:00 p.m.-3:30 p.m. Meet-the-Expert

Professional Advancement Sessions 3:30 p.m.-4:30 p.m. Career Development Roundtables Session

4:30 p.m.-6:30 p.m. Scientific Symposium 2: Cancer Prevention

Dead Sea 1 & 2

and Epidemiology

**Chairperson: Christopher P. Wild,** International Agency for Research on Cancer, Lyon, France

**Biomarkers in cancer prevention** Christopher P. Wild

Epidemiology in cervical cancer prevention

Mahboobeh Safaeian, National Institutes of Health, Division of Cancer Epidemiolgy and Genetics, Bethesda, MD, USA

Translating cancer prevention strategies to clinics and communities

Karen Glanz, University of Pennsylvania, Philadelphia, PA, USA

### Tuesday, March 9, 2010

# 9:00 a.m.-11:00 a.m. Scientific Workshop 2: Pharmacogenomics

Dead Sea 1 & 2

**Chairperson: Jeffrey M. Trent,** Translational Genomics Research Institute, Phoenix, AZ, USA

Using biointelligence as a tool for reducing dimensionality and prioritizing genetic determinants of drug response

Jeffrey M. Trent

Recent discoveries in neuroblastoma genetics provide translational opportunities

John M. Maris, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Sage: Together building probabilistic causal disease models via an open access contributor network Stephen H. Friend, Sage Bionetworks, Seattle, WA, USA

**Using the genome to guide clinical cancer care** Howard L. McLeod, University of North Carolina, Chapel Hill, NC, USA

# 11:30 a.m.-1:30 p.m. Scientific Symposium 3: Novel Therapeutics

Dead Sea 1 & 2

Chairperson: Tom Curran, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Use of mouse models in preclinical studies of children's brain tumors

Tom Curran

Targeting the hedgehog pathway in cancer Frederic J. de Sauvage, Genentech, Inc., South San Francisco, CA, USA

### Oncogenomics as basis for cancer therapy development

Axel Ullrich, Max Planck Institute of Biochemistry, Martinsried, Germany

Targeting intrinsic subtypes in breast cancer

Lisa A. Carey, University of North Carolina, Chapel Hill, NC, USA

1:30 p.m.-2:30 p.m. Lunch

Terrace

2:30 p.m.-4:15 p.m. Proffered Talks Session

Dead Sea 1 & 2

Speakers to be announced

4:30 p.m.-6:30 p.m. Scientific Workshop 3: Non-Coding RNAs and Tumor Biology

Dead Sea 1 & 2

**Chairperson: George A. Calin,** UT M. D. Anderson Cancer Center, Houston, TX, USA

Non-coding RNAs for medical practice George A. Calin

Pinning down microRNA target sites in animals

Amy E. Pasquinelli, University of California, San Diego, La Jolla, CA, USA

Causes and consequences of microRNA dysregulation in cancer

Carlo M. Croce, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

### Wednesday, March 10, 2010

9:00 a.m.-11:00 a.m. Scientific Workshop 4:
Biomarkers and
Molecular Imaging
for Early Detection
and Response

Dead Sea 1 & 2

**Chairperson: Sanjiv Sam Gambhir,** Stanford University, Stanford, CA, USA

Novel strategies for earlier cancer detection using nanotechnology

Sanjiv Sam Gambhir

Genetic strategies for combined blood-based screening and imaging

Kurt R. Zinn, University of Alabama, Birmingham, AL, USA

Tumor pH and hypoxia as metabolic targets for anticancer therapy

Robert J. Gillies, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Advances in molecular imaging of cancer

Juri G. Gelovani, UT M. D. Anderson Cancer Center, Houston, TX, USA

### 11:30 a.m.-1:30 p.m. Scientific Symposium 4: Cancer Stem Cells

Dead Sea 1 & 2

**Chairperson: William S. Dalton,** H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Dissecting mammogenesis to facilitate identification, isolation and characterization of mammary stem cells Geoffrey M. Wahl, Salk Institute Cancer Center, La Jolla, CA, USA

Normal and chronic myeloid leukemia stem cells Connie J. Eaves, Terry Fox Laboratory, BC Cancer Research

Centre, Vancouver, BC, Canada

Therapeutic targeting of breast cancer tumor initiating cells

Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX, USA

1:30 p.m.-3:30 p.m. Poster Session B and Lunch

Wadi Rum 1 & 2

3:00p.m.-3:30 p.m. Meet-the-Expert Professional Advancement Sessions

3:30 p.m.-6:00 p.m. Scientific Symposium 5: Cultural Considerations

in Cancer Research and Treatment

Dead Sea 1 & 2

6:00 p.m.-7:00 p.m. Public Reception

Terrace

Chairperson: Samir N. Khleif, National Cancer Institute,

Bethesda, MD, USA

7:00 p.m.-10:00 p.m. Conference Closing Dinner

> Jordan Valley Marriott Resort and Spa

Melanoma: New insights, new biomarkers

Alexander M. M. Eggermont, Erasmus Medical Center,

Rotterdam, The Netherlands

Cancer research in Asia: Challenges and opportunities

John E.L. Wong, The Yong Loo Lin School of Medicine,

Singapore

Title to be announced

Serigne M. Gueye, University Cheikh Anta Diop, Dakar-Etoile, Senegal